Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Roivant Sciences Ltd. (ROIV : NSDQ)

• Company Description    Roivant Sciences is a biopharmaceutical company dedicated to improving the delivery of healthcare to patients. Roivant Sciences, formerly known as Montes Archimedes Acquisition Corp., is based in NEW YORK. Number of Employees: 750

• Price / Volume Information    Yesterday's Closing Price: $26.45 Daily Weekly Monthly 20 Day Moving Average: 6,771,100 shares Shares Outstanding: 695.49 (millions) Market Capitalization: $18,395.76 (millions) Beta: 1.22 52 Week High: $27.94 52 Week Low: $8.73 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 13.52% 15.32% 12 Week 30.49% 24.81% Year To Date 21.89% 23.50%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 7th Floor 50 Broadway - LONDON,X0 SW1H 0DB GBR ph: 44-20-7400-3347 fax: - keyur.parekh@roivant.com https://roivant.com

• General Corporate Information    Officers Matthew Gline - Chief Executive Officer and Director Mayukh Sukhatme - President and Chief Investment Officer Richard Pulik - Chief Financial Officer Jennifer Humes - Chief Accounting Officer Keith Manchester - Director Peer Information Roivant Sciences Ltd. (CORR.) Roivant Sciences Ltd. (RSPI) Roivant Sciences Ltd. (CGXP) Roivant Sciences Ltd. (BGEN) Roivant Sciences Ltd. (GTBP) Roivant Sciences Ltd. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: G76279101 SIC: 2834 Fiscal Year Fiscal Year End: March Last Reported Quarter: 12/01/25 Next Expected EPS Date: 06/04/26 Share - Related Items Shares Outstanding: 695.49 Most Recent Split Date: (:1) Beta: 1.22 Market Capitalization: $18,395.76 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.38 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.55 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 06/04/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 3.70 Price/Cash Flow: - Price / Sales: 1,382.10 EPS Growth vs. Year Ago Period: -80.00% vs. Previous Quarter: 10.00% Sales Growth vs. Year Ago Period: -77.83% vs. Previous Quarter: 27.24% ROE 12/31/25 - -19.04 09/30/25 - -16.43 06/30/25 - -15.90 ROA 12/31/25 - -18.15 09/30/25 - -15.68 06/30/25 - -14.95 Current Ratio 12/31/25 - 30.66 09/30/25 - 33.71 06/30/25 - 40.54 Quick Ratio 12/31/25 - - 09/30/25 - 33.70 06/30/25 - 40.54 Operating Margin 12/31/25 - -7,076.27 09/30/25 - -4,110.65 06/30/25 - -3,613.43 Net Margin 12/31/25 - -6,079.94 09/30/25 - -1,839.58 06/30/25 - -2,111.79 Pre-Tax Margin 12/31/25 - -6,925.09 09/30/25 - -4,259.30 06/30/25 - -4,008.14 Book Value 12/31/25 - 7.15 09/30/25 - 6.97 06/30/25 - 7.05 Inventory Turnover 12/31/25 - - 09/30/25 - - 06/30/25 - - Debt-to-Equity 12/31/25 - 0.00 09/30/25 - 0.00 06/30/25 - 0.00 Debt-to-Capital 12/31/25 - 0.00 09/30/25 - 0.00 06/30/25 - 0.00

Powered by Zacks Investment Research ©